Financial Data and Key Metrics Changes - The fourth quarter results met expectations with PET Labs generating $4.2 million in revenue for the year, indicating stability in the business [4] - The company has not provided guidance for the current year or the first quarter, focusing instead on the startup of three manufacturing plants for commercial production [5][6] Business Line Data and Key Metrics Changes - The Carbon-14 plant faced feedstock issues but is now enriching Carbon-14 after receiving necessary materials [5] - The Silicon-28 plant encountered commissioning challenges but has been successfully repaired and is operational [6][7] - Ytterbium-176 has started commercial enrichment after overcoming technical difficulties with equipment [9] Market Data and Key Metrics Changes - Expected production for Ytterbium is around one kilogram per year, with a projected price of $20,000 per gram [19] - Carbon-14 has a take-or-pay contract with a minimum of $2.5 million annually, with potential for higher revenue [19] - PET Labs is expected to grow revenue from $4 million last year due to significant investments [21] Company Strategy and Development Direction - The company plans to construct additional plants for Nickel-64, Gadolinium-160, and Lithium-6, with construction timelines dependent on regulatory approvals [22][24] - There are ambitions to expand manufacturing capabilities in North America through partnerships to navigate regulatory challenges [29][30] - The company aims to build more isotope enrichment facilities in various regions to enhance its market presence [76] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving cash flow breakeven in the second half of the year, supported by a strong balance sheet [55] - Regulatory discussions with the South African government are progressing positively, with plans to start production in the second half of the year [69][81] - The company is focused on addressing regulatory and licensing challenges to expedite plant construction and operations [68][70] Other Important Information - The company has received significant interest in Ytterbium-176, with two kilograms of indicated demand from customers [38] - Management highlighted the importance of securing supply agreements before finalizing contracts for Ytterbium [36] - The company is actively working on enhancing sell-side coverage to improve market perception [87] Q&A Session Summary Question: What are your expected revenues for ASPI in 2025? - The company has not provided specific guidance but indicated that signed contracts can help estimate an annualized run rate [18] Question: Can you provide guidance on the timing of the construction of new plants? - Construction timelines depend on obtaining export permits, which are currently in process [24] Question: When do you expect to start enriching product in Pelindaba? - The timeline is contingent on regulatory approval, with hopes to begin this year [81] Question: How are market prices changing for the isotopes? - Carbon-14 is fixed at $24,000 per gram, while Ytterbium is facing push-back at $20,000 per gram, and Silicon-28 may see a price reduction to stimulate demand [82][84] Question: Are there any updates on the QLE spinout? - The company is working on necessary permits and documentation for the spinout, with no specific timeline provided [35][33] Question: What keeps management awake at night now that production has started? - Competing against government-backed entities remains a concern, particularly regarding capital costs for building plants [120]

Financial Data and Key Metrics Changes - The fourth quarter results met expectations with PET Labs generating $4.2 million in revenue for the year, indicating stability in the business [4] - The company has not provided guidance for the current year or the first quarter, focusing instead on the startup of three manufacturing plants for commercial production [5][6] Business Line Data and Key Metrics Changes - The Carbon-14 plant faced feedstock issues but is now enriching Carbon-14 after receiving necessary materials [5] - The Silicon-28 plant encountered commissioning challenges but has been successfully repaired and is operational [6][7] - Ytterbium-176 has started commercial enrichment after overcoming technical difficulties with equipment [9] Market Data and Key Metrics Changes - Expected production for Ytterbium is around one kilogram per year, with a projected price of $20,000 per gram [19] - Carbon-14 has a take-or-pay contract with a minimum of $2.5 million annually, with potential for higher revenue [19] - PET Labs generated $4 million last year, with expectations for growth due to recent investments [21] Company Strategy and Development Direction - The company plans to construct additional plants for Nickel-64, Gadolinium-160, and Lithium-6, with construction timelines dependent on regulatory approvals [22][24] - There are ambitions to expand manufacturing capabilities in North America through partnerships to navigate regulatory challenges [29][30] - The company aims to build more isotope enrichment facilities in various regions to enhance its market presence [76] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving cash flow breakeven in the second half of the year, supported by a strong balance sheet [55] - Regulatory discussions with the South African government are progressing positively, with plans to start production at Pelindaba [68][81] - The company is actively engaging with potential U.S. partners, including TerraPower, to enhance its market position [61] Other Important Information - The company has seen a significant increase in headcount from approximately 130 to 150, with plans for further selective hiring [78] - Management is focused on improving financial reporting processes to ensure timely results [94] Q&A Session Summary Question: What are your expected revenues for ASPI in 2025? - The company has not provided specific guidance but indicated that signed contracts can help estimate an annualized run rate [18] Question: Can you provide guidance on the timing of the construction of new plants? - Construction timelines depend on obtaining necessary export permits, with the first plant expected to come online later this year [22][24] Question: What is the current status of the QLE spinout? - The spinout is contingent on securing a location for the uranium plant and achieving cash flow breakeven [33][35] Question: How are market prices changing for the isotopes? - Carbon-14 is fixed at $24,000 per gram, while Ytterbium is facing push-back at $20,000 per gram, and Silicon-28 may see a price reduction to stimulate demand [82][84] Question: Are there any new emerging competitors in the market? - Currently, there are no significant new competitors identified in the market for the isotopes being produced [96] Question: What keeps management awake at night now that production has started? - Competing against government-backed entities remains a concern, particularly regarding capital costs for building plants [119]

Core Insights - ASP Isotopes Inc. has commenced the production of highly enriched Ytterbium-176, a critical material for oncology treatments, following the successful commissioning of its Quantum Enrichment facility in Pretoria, South Africa [3][4][5] - The company aims to achieve 99.75% enrichment for Ytterbium-176 and plans to offer it for commercial sale in 2025 [5][8] - ASP Isotopes is also planning to construct additional enrichment facilities for Nickel-64, Gadolinium-160, and Lithium-6/7 based on the success of the Ytterbium-176 facility [10][12] Company Developments - The Ytterbium-176 enrichment facility is the company's third in South Africa and utilizes a novel laser-based Quantum Enrichment method, which is believed to be more efficient and scalable than traditional methods [4][5] - The construction phase of the facility took only 8 months, significantly shorter than the anticipated 18 months, and the commissioning phase took 6 months [5] - The company has received considerable interest from customers in North America, Europe, and Asia for Ytterbium-176, indicating a strong demand for this isotope [9] Market Context - The beta-emitting radiopharmaceutical market, including drugs like Novartis' Pluvicto, is projected to exceed $15 billion annually in the next decade, with consensus forecasts for Pluvicto alone exceeding $4 billion [8] - There are significant supply-side challenges for essential radioisotopes, with reports of treatment delays due to drug availability [8][9] - ASP Isotopes aims to be one of the few suppliers of commercial quantities of Ytterbium-176 and similar isotopes in the Western world, addressing current supply chain issues [8][9] Future Plans - The company is in discussions with nuclear regulatory authorities for the authorization to construct HALEU uranium enrichment facilities using Quantum Enrichment technology in South Africa and other countries [2][16] - There is an anticipated demand for Lithium-6 and Lithium-7 for future nuclear fusion power plants and advanced nuclear reactors, with no current Western producers of Lithium-6 in commercial quantities [13][15] - The company believes its Quantum Enrichment process could produce HALEU at competitive prices, potentially accelerating the adoption of new nuclear energy solutions [14][15]

Financial Performance - The company reported a net loss of $32.4 million for the year ended December 31, 2024, compared to a net loss of $16.3 million for the year ended December 31, 2023, resulting in an accumulated deficit of $56.2 million as of December 31, 2024[143]. - The company has cash of approximately $61.9 million as of December 31, 2024, which is expected to fund operations for at least the next 12 months[154]. - The company identified a material weakness in internal control over financial reporting, related to insufficient documentation and personnel in the finance and accounting function[287]. - The company expects to enhance formal documentation and hire additional resources to remediate the identified material weaknesses[288]. - A hypothetical 100 basis point increase or decrease in interest rates would not have had a material impact on the company's financial results[400]. - Foreign currency transaction gains and losses have not been material to the company's financial statements, and no formal hedging program is in place[401]. - The company does not believe that inflation significantly impacted its results of operations for the period presented[402]. - The company may face substantial costs and management diversion due to potential securities class action litigation following stock price volatility[293]. Research and Development - The company has incurred significant research and development expenses and anticipates continued significant losses for the foreseeable future, with limited commercial activity expected in the U.S. over the next two to three years[144]. - The company is still in the preliminary stages of research and development for isotopes and has not yet demonstrated the ability to produce commercial quantities using its technologies[146]. - The company is conducting R&D for isotopes using ASP technology and Quantum Enrichment technology, but has not yet produced any isotopes at commercial scale[160]. - The company plans to research uranium enrichment using Quantum Enrichment technology, which faces significant regulatory hurdles[161]. - The success of the company’s future revenues will depend on the successful development and commercialization of future isotopes[162]. - The company expects to incur significant commercialization expenses related to product sales, marketing, and distribution for future isotopes[155]. Regulatory and Compliance Risks - The company is dependent on obtaining regulatory approvals for future isotopes, which may take significant time and could impact its ability to enter the nuclear energy space[140]. - Regulatory approval for isotopes may be lengthy and uncertain, impacting the company's ability to generate revenue from its products[170][172]. - Regulatory approval for stable isotopes in one jurisdiction does not guarantee approval in others, which could materially impact commercialization efforts[190]. - Obtaining regulatory licenses for stable isotopes may be a costly and time-consuming process, potentially delaying market introduction[191]. - Changes in laws or new regulations could negatively impact the company's performance and ability to collaborate with partners[197]. Competition and Market Risks - The company faces substantial competition in the isotope market, which may hinder its ability to develop or commercialize its products[179][180]. - The company relies on a limited number of suppliers for components, and any disruption could adversely affect its strategic plans[165][167]. - Development activities in South Africa could be disrupted by various factors, including power outages and natural disasters, impacting the company's operations[168]. Intellectual Property and Legal Risks - The company has not yet protected its intellectual property through patents, relying instead on trade secrets and non-disclosure agreements[199]. - The lack of patent protection may result in competitors replicating the company's technology, impacting revenue generation[201]. - The company cannot assure that non-disclosure agreements will effectively control access to its proprietary information, increasing risks of breaches[202]. - The company may face significant costs and management distractions due to potential infringement claims related to its ASP technology and Quantum Enrichment technology[205]. - Future claims alleging infringement could result in costly arbitration or litigation, potentially affecting the company's financial condition[206]. - The company may face substantial litigation expenses and management distractions due to potential claims of intellectual property infringement, which could harm business operations[224]. - There is a risk that third parties may assert infringement claims against the company, leading to potential damages, licensing fees, or redesigning of products[224]. Capital and Funding - The company plans to seek additional capital through public and private equity offerings, debt financings, and strategic partnerships, which may dilute stockholder ownership[158]. - If the company cannot raise additional capital, it may need to delay or terminate product development efforts[159]. - The development and commercialization of future isotopes will require substantial additional capital, which may not be available on acceptable terms[210]. - The company expects to need significant additional capital in the future for planned operations, including development activities and commercialization efforts[262]. - The company may sell Common Stock or other equity securities, which could result in material dilution to existing stockholders[264]. Management and Organizational Risks - The company is highly dependent on its senior management team, and the loss of any key members could impede research, development, and commercialization objectives[233]. - As of December 31, 2024, the company employed 136 people, with 127 located in South Africa, indicating a need for organizational expansion to manage growth effectively[237]. - Attracting and retaining qualified personnel is critical, as competition for talent in the biotechnology and pharmaceutical sectors is intense[235]. - The company does not maintain "key person" life insurance for its executives, which could pose a risk to business continuity[236]. - The company may face challenges in managing growth, which could result in operational inefficiencies and loss of business opportunities[237]. Information Technology and Security Risks - The company is dependent on information technology systems and infrastructure, which are critical for operating its business and managing sensitive information[240]. - Significant disruptions to information technology systems could result in financial, legal, regulatory, and reputational harm to the company[241]. - The company has implemented security measures to protect its information technology systems, but there is no assurance that these measures will prevent security incidents[243]. - The company may face increased costs and legal exposure due to potential data security incidents and breaches of privacy obligations[242]. Stock and Market Risks - The company is currently listed on The Nasdaq Capital Market, and failure to maintain compliance with listing standards could adversely affect stock price and liquidity[278]. - If the company fails to maintain its listing on Nasdaq, it may face significant adverse effects on liquidity and market price of its Common Stock[279]. - The exclusive forum provisions in the company's amended and restated certificate of incorporation may limit stockholders' ability to bring claims in favorable judicial forums, potentially discouraging lawsuits[277]. - The trading price of the company's Common Stock has fluctuated significantly since its IPO, influenced by various factors including market conditions and regulatory decisions[256]. - The company may be subject to future short seller publications, which could negatively impact its brand, reputation, and financial condition[254].

Core Viewpoint - ASP Isotopes Inc. is set to release its fourth quarter and fiscal year 2024 financial results on March 31, 2025, followed by a webinar to discuss the results and future strategies [1][2] Company Overview - ASP Isotopes Inc. is a development stage advanced materials company focused on producing isotopes for various industries using proprietary Aerodynamic Separation Process (ASP technology) [2] - The company aims to commercialize highly enriched isotopes for healthcare and technology sectors, and plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology [2] Market Demand - There is an increasing demand for isotopes such as Silicon-28 for quantum computing, Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications [3] - ASP technology is particularly suitable for enriching both low and heavy atomic mass molecules [3]

- Silicon-28 is an isotope that is believed to assist in enabling quantum computing and improving the performance of next generation semiconductors for artificial intelligence. - The Company expects to ship commercial product during 2Q25. - The Company has already entered into two purchase agreements with US-based customers for kilogram quantities of Silicon-28 and is in discussions with multiple other global customers for kilogram quantities. WASHINGTON, March 27, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. ...

- The Company has commenced commercial production of enriched Carbon-14 at its first Aerodynamic Separation Process (ASP) enrichment facility. - The Company expects to ship commercial product around the middle of the year. - The Company previously entered into a multi-year, take-or-pay contract with a Canadian customer, valued at a minimum of approximately $2.4 million per annum. WASHINGTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced mate ...

ASP Isotopes invites institutional investors to attend the upcoming virtual event by contacting their Canaccord Genuity representative Paul Mann, Chairman and Chief Executive Officer of ASP Isotopes, will participate in a panel discussion on the future of nuclear fission. The panel will also include representatives from TerraPower and Elementl Power WASHINGTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the d ...

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ASP Isotopes Inc. (NASDAQ: ASPI). Shareholders who purchased shares of ASPI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/asp-isotopes-inc-loss-submission-form/?id=126300&from=3 CLASS PERIOD: October 30 ...

PHILADELPHIA, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Nationally recognized law firm Berger Montague PC informs investors that a lawsuit was filed against ASP Isotopes Inc. (“ASP Isotopes” or the “Company”) (NASDAQ: ASPI) on behalf of purchasers of ASP Isotopes securities between October 30, 2024 and November 26, 2024, inclusive (the “Class Period”). Investors that suffered losses from ASP ISOTOPES (NASDAQ: ASPI) investments can follow the link below for more information regarding the lawsuit: CLICK HERE to learn ...